Correlation Of Mutation Status Between Tissue And Blood-Drop Liquid Biopsies From Ovarian Cancer Patients Following Chemotherapy.

e13108Background: Peripheral circulating cell-free DNA (cfDNA) has great promise for targeted therapy and monitoring tumor clonal evolution during treatment, thus overcoming the limitations of invasive tissue biopsy. However, the requirement of large sample input, low extraction efficiency, and poor yield, coupled with a labor-intensive and time-consuming procedure in order to obtain a liquid biopsy presents a major challenge. Methods: Circulogene has developed a highly efficient and high yield cfDNA enrichment technology from only 20ul of blood. We were able to sequence cfDNA and tumor DNA from 14 de-identified plasma and tumor tissue samples pre- and post- chemotherapy for a total of 56 samples. We ascertained the mutation status of five therapeutically targetable genes implicated in ovarian cancer: TP53, PIK3CA, PTEN, KRAS, and BRAF. These genes were interrogated by deep next-generation sequencing, and concordance was determined between matched tissue and plasma, and pre- and post-treatment samples. Re...